EWTX in the 13F filings
Edgewise Therapeutics Inc · CUSIP 28036F105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 2 listed it in both
- Shares listed
- 9,317,970
- combined, among listed positions
- Reported value
- $231m
- combined, at the quarter end
Among the 92 comparable managers: 16 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +904,931.
Managers listing EWTX in Q4 2025
22 of 22 holders
Largest increases and reductions, by shares
Increases
- AllianceBernstein LPexisting position · 1,036,170 shares now+958,910
- Marshall Wace LLPnew position · 681,921 shares now+681,921
- Fidelity (FMR LLC)existing position · 692,955 shares now+439,630
- Balyasny Asset Management LLCnew position · 151,905 shares now+151,905
- Citadel Advisors LLCexisting position · 123,097 shares now+100,780
Reductions
- Millennium Management LLCexisting position · 126,436 shares now-598,989
- Janus Henderson Group Ltdexisting position · 4,566,850 shares now-412,481
- D. E. Shaw & Co.existing position · 394,695 shares now-282,866
- Neuberger Berman Group LLCexisting position · 127,136 shares now-92,510
- Artisan Partners LPexisting position · 704,077 shares now-14,098
New positions and exits
New (7)
Exited (3)
- Squarepoint Ops LLCwas $1.2m
- Jane Street Group LLCwas $1.1m
- ExodusPoint Capital Management LPwas $238k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2021 | 3 | $186m | n.a. | n.a. |
| Q2 2021 | 2 | $66m | n.a. | n.a. |
| Q3 2021 | 2 | $51m | n.a. | n.a. |
| Q4 2021 | 2 | $48m | n.a. | n.a. |
| Q1 2022 | 2 | $30m | n.a. | n.a. |
| Q2 2022 | 2 | $28m | n.a. | n.a. |
| Q3 2022 | 2 | $49m | n.a. | n.a. |
| Q4 2022 | 2 | $43m | n.a. | n.a. |
| Q1 2023 | 2 | $35m | n.a. | n.a. |
| Q2 2023 | 2 | $49m | n.a. | n.a. |
| Q3 2023 | 2 | $37m | n.a. | n.a. |
| Q4 2023 | 4 | $85m | 3 | 0 |
| Q1 2024 | 4 | $102m | 2 | 2 |
| Q2 2024 | 5 | $86m | 3 | 2 |
| Q3 2024 | 6 | $217m | 4 | 1 |
| Q4 2024 | 5 | $217m | 3 | 2 |
| Q1 2025 | 5 | $184m | 3 | 2 |
| Q2 2025 | 3 | $105m | 3 | 1 |
| Q3 2025 | 2 | $92m | 0 | 2 |
| Q4 2025 | 2 | $131m | 16 | 9 |
| Q1 2026 | 3 | $212m | 15 | 10 |
| Q2 2026 | 3 | $281m | 14 | 11 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
EWTX and LLY →EWTX and JNJ →EWTX and VRTX →Choose a stock to compare with EWTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own EWTX, latest filings →Back to the 13F Explorer →